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Background: Free fatty acids (FFAs) play importance roles in the development of diabetes and cardiovascular
diseases. We measured serum FFA levels from type 2 diabetes mellitus (T2DM) and acute myocardial infarction
(AMI) patients and assay the correlation between serum FFA levels and related factors. The present study was
undertaken to investigate a possible relation between the changes in serum free fatty acid concentration with
acute myocardial infarction and type 2 diabetes mellitus.
Methods: The study population consisted of 540 healthy individuals and 103 patients with T2DM, 59 patients with
AMI and 21 volunteers. Serum FFAs were measured with high pressure liquid chromatography. Blood urea nitrogen
and uric acid were measured in clinical laboratory, as were glycemic, lipid and blood routine parameters. We
selected 242 individuals with age over 60 years, 143 healthy individuals and 52 patients with T2DM, 47 patients
with AMI were incorporated into three groups as control group, T2DM group and AMI group. Associations were
analyzed with stepwise regression analysis with adjusted for age, sex, body mass index.
Results: Serum FFA levels were significantly higher in the age over 60 years individuals compared to 20 ~ 50 years
(logFFA μmmol/L:2.60 ± 0.16 vs. 2.73 ± 0.18, P < .001) in the healthy group. We found lower FFA levels in the AMI
compared to the T2DM and control group (2.64 ± 0.22 vs. 2.72 ± 0.13&2.72 ± 0.16, respectively, P < .05&P < 0.01) in the
age over 60, fasting blood glucose level higher in the AMI and T2DM (5.78 ± 1.32&7.75 ± 2.93 mmol/L vs. 4.90 ±
0.47 mmol/L, P < .01&P < .001) compared with the normal group, HDL level (1.01 ± 0.22&0.98 ± 0.18 mmol/L vs.1.30 ±
0.22 mmol/L, P < .001&P < .001). With stepwise regression analysis, the serum FFA levels was positively associated with
the HDL in the control group (YlogFFA = 2.32 + 0.33XHDL, R = 0.26, P < .01) and T2MD (YlogFFA = 2.46 + 0.27XHDL, R = 0.36,
P < .05), AST in AMI (YlogFFA =2.24 + 0. 015XAST, R = 0.49, P < .01).
Conclusions: Compared to control group, serum FFA levels were decreased only in AMI group, while HDL level was
increased in both AMI and T2DM group. The serum FFA levels were positive association with the HDL level in both
T2DM and control group, FFA levels were positive association with AST in AMI.
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More than 347 million patients had diabetes around the
world in 2008 [1], the World Health Organization pro-
jected that diabetes was likely to become the 7th leading
cause of death in 2030 [2]. Diabetes increases the risk of
cardiovascular disease and stroke, about 50% of people
with diabetes die of cardiovascular disease [3]. Diabetes-
associated atherosclerosis has been estimated to affect
5-8% of the general population and was by itself a major
cause of death among diabetic patients with accounting
for 50% of mortality [4]. Dyslipidemia contributes to
diabetes-associated atherosclerosis and even to insulin re-
sistance [5], and strong evidence supports the role of free
fatty acids (FFAs) in promoting insulin resistance [6]. In-
sulin resistance increases atherogenesis and induces proin-
flammatory activities on vascular. Hyperglycemia caused
feedback loop, increasing lipolysis and leading to a chronic
exposure to the FFAs [6-8].
Cardiovascular diseases (CVDs) have emerged as the
dominant contributor to total global, and the total number
of CVDs deaths increased from 14.4 million in 1990 to 17
million in 2008. More than seven million patients are re-
portedly diagnosed with AMI each year, 90% of myocar-
dial infarctions are attributable to modifiable risk factors
as smoking, dyslipidemia, hypertension and diabetes [9].
Some studies have recently reported that STEMI patients
with high glucose are related to adverse impact on
survival, and the plasma FFAs concentration has been
associated with lip toxicity, apoptosis, and risk of diabetes
mellitus and coronary heart disease [10].
Circulating FFAs are albumin-bound lipid molecules
principally derived from adipose tissue lipolysis [11].
The FFAs is a major fuel in mammals besides glucose. It
is established that the excess supply of FFAs could sup-
press food intake and reduce hepatic glucose output. An
overabundance of FFAs, due to exogenous lipid infusions
or obesity, can lead to insulin resistance, vascular dys-
function, and myocardial dysfunction. Additional studies
are needed to explore biological mechanisms that FFAs
may influence the happen of AMI.
Methods
Subjects
This study was carried out at the Zhongnan Hospital of
Wuhan University and Renmin Hospital of Wuhan Univer-
sity. The research protocol was approved by the Medical
Ethics Committee of the Zhongnan Hospital of Wuhan
University. All individuals provided informed consent with
verbally or in writing. The normal group population was
selected from those who underwent a comprehensive
health examination at Zhongnan Hospital of Wuhan Uni-
versity, Renmin Hospital of Wuhan University. The study
subjects included 103 T2DM and 59 AMI patients who
had been hospitalized at two departments: Department ofendocrinology and cardiovascular medicine in Zhongnan
Hospital of Wuhan University. The 21 volunteers were
graduate students from the Center for Gene Diagnosis of
Zhongnan Hospital of Wuhan University. The health
examination individuals were selected for participation
based on the following criteria: liver, kidney function and
blood test were in the normal range for the most parame-
ters, and without other systemic disease history.
Type 2 diabetes was defined according to the American
Diabetes Association (ADA) [12]. Any one of the following
criteria meets the diagnosis for T2DM (In the absence of
unequivocal hyperglycemia, criteria 1–3 should be con-
firmed by repeat testing): (1) HbA1c ≥6.5%. (2) FPG ≥7.0
mmol/l. (3) Two-hour plasma glucose ≥11.1 mmol/l dur-
ing an OGTT. (4) In a patient with classic symptoms of
hyperglycemia or hyperglycemic crisis, a random plasma
glucose ≥11.1 mmol/l. Patients were excluded for the fol-
lowing reasons: (1) Patients who were diagnosed with type
1 diabetes mellitus (2) Patients who were complicated with
cardiovascular disease, viral hepatitis, tumor, autoimmune
disease, serious liver or kidney dysfunction (3) patients
who use lipid-lowering drugs (e.g. Lipitor and Zocor, etc,
which are in a class of drugs known as statins).
AMI was defined according ESC/ACCF/AHA/WHF
[13,14]. Detection of a rise of cardiac troponin (cTn)
with at least one above the 99th percentile upper refer-
ence limit (cTnT ≥0.01 ng/L) and with at least one of the
following: (1) Symptoms of ischaemia: chest pain lasting
30min or longer. (2) New or presumed new significant
ST-segment-T wave (ST-T) changes or new left bundle
branch block (LBBB). (3) Development of pathological Q
waves in the ECG. (4) Imaging evidence of new loss of
viable myocardium or new regional wall motion abnor-
mality. (5) Identification of an intracoronary thrombus
by angiography or autopsy. Patients were excluded for
the following reasons: (1) Previous myocardial infarction.
(2) Patients who were complicated with diabetes melli-
tus, viral hepatitis, tumor, autoimmune disease, serious
liver or kidney dysfunction. (3) Patients who used lipid-
lowering drugs (e.g. Lipitor and Zocor, etc. which are in
a class of drugs known as statins).
Study population
Height (cm) and weight (kg) were measured in the stand-
ing position when health examination or admission. Ven-
ous blood samples were collected after overnight fasting
for T2DM patients, healthy examination individuals and
volunteers. Venous blood samples were collected for AMI
patients within 4 hours of admission. Serum samples were
prepared by centrifugation at 2000 rpm for 10 min at 4°C.
Blood routine parameters were measured using the auto-
matic hematology analyzer (Beckman-CoulterLH750, USA).
The inter-assay coefficients of variation (CV%) amounts to
3.6% and 2.9% in the higher normal and lower normal range
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terol (TC), triglyceride (TG) and high-density lipoprotein
cholesterol (HDL-c), low-density lipoprotein cholesterol
(LDL-c), Serum aminotransferase (ALT) and aspartate
aminotransferase (AST), serum urea nitrogen(BUN), uric
acid concentrations were measured using the automated
chemistry analyzer (Olympus AU5400 biochemistry
analyzer, Japan). The inter-assay coefficients of variation
(CV%) amounts to 3.9% and 2.7% in the higher normal
and lower normal range respectively. Serum samples for
FFAs assays were stored at −80°C until analysis. Serum
FFA levels were measured with high pressure liquid chro-
matography (HPLC) within one hour after rehydration.
Statistical analysis
SPSS 13.0 software was used for statistical analysis. Cat-
egorical variables were expressed as proportions and com-
pared between groups using the X2 test. Continuous data
are expressed as mean ± SD for normally distributed vari-
ables or median (inter quartile range) for others. The
paired t-test was used to compare continuous variables.
Unavailable relationships were calculated with Pearson
correlation coefficients. Comparison of the groups by
ANOVA was followed by SNK-q test to determine differ-
ences between individual groups. Multivariable stepwise
regression analyses were performed to determine the inde-
pendent correlation factors to FFA. Because of skewed
distribution, the values of FFA were transformed in loga-
rithmically for analysis. The level of significance was set at
P < .05.
Results
The stability of FFAs
A total of 21 volunteer subjects were enrolled in this
study. Mean age was 26.7 ± 2.3 years, and 33% were men.
The serum sample was stored at room temperature (1 h, 4
h, 8 h, 24 h) and at 4°C 4 h, and plasma sample at roomFigure 1 The change of FFA levels with different storing temperature
at 4°C 4 h, others stored at room temperature .Scatter plots show relations
compared to room temperature 1 h. ###P < .001, paired t-test: compared totemperature 1 h and at 4°C 4 h. There was no significant dif-
ference in serum FFA levels between the room temperature
1 h and 4°C 4 h (407.3 ± 148.4 mmol/L vs. 406.2 ±
148.1 mmol/L, P = 0.19). The FFA levels began to increase
in those groups under room temperature (4 h: 416.9 ±
149.2 mmol/L; 8 h: 419.5 ± 149.2 mmol/L; 24 h: 513.8 ±
151.2 mmol/L; P < .001) compared to room temperature
1 h (407.3 ± 148.4 mmol/L) (Figure 1A). Plasma FFA levels
were significant lower compared to the serum levels
(room temperature 1 h: 351.3 ± 137.9 mmol/L vs. 407.3 ±
148.4 mmol/L; P < .001).The scatter plot also showed an
elevated of FFA levels with the storing time lasted (R2 =
0.957, P < .001, Figure 1B).
The FFA levels in different age and gender.
We divided 540 healthy individuals into six sub-groups
(Figure 2). There was a significant difference among the
six sub-groups after adjusted for sex and BMI, the FFA
levels had a trend of increasing with the age, but not
enough to achieved statistically significant among the
age among 20 ~ 50 years and 60 ~ years. We found no
difference between sexes (Table 1).
Baseline characteristics
Baseline characteristics were shown in Table 2. A total
of 242 eligible consecutive individuals were included
which age was over 60 years between June 2013 to October
2013. There were 143, 52 and 47 subjects in the control
group, T2DM and AMI, respectively. All data were in a
normal distribution exclude ALT, AST and FFAs.
Associations of FFAs with other conceivable factors
In this part, 242 subjects were chosen according to age
greater than or equal to 60 (129/242 were men; 71.0 ±
6.8 years). There were 143, 52 and 47 subjects in the con-
trol group, T2DM and AMI, respectively. We compared
the three groups with one-way ANOVA (Figure 3). Serumand time. The histogram showed FFA levels (A) 4△represents stored
hips of storing time (h) and serum FFA (B). ***P < .001, paired t-test:
4°C 4 h. The dotted line was a virtual-line.
Figure 2 The change of FFA levels in different age. FFA levels (A) and BMI (B) in different group. ANOVA was followed by SNK-q test to determine
differences between individual groups; Data are mean ± SD (N.S.: no statistically significant.
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significantly higher in individuals with T2DM and AMI
compared to control, as TG (2.02 ± 1.29 mmol/L&1.63 ±
0.88 mmol/L vs. 1.12 ± 0.33 mmol/L, P < .001&P < .001)
(Figure 3A) and glucose (7.75 ± 2.93 mmol/L&5.78 ±
1.32 mmol/L vs. 4.90 ± 0.49 mmol/L, P < .001&P < .01)
(Figure 3D). The HDL levels were lower in T2DM (0.98 ±
0.18 mmol/L, P < .001) and AMI (1.01 ± 0.22 mmol/L,
P < .001) compared to control group (1.30 ± 0.22 mmol/L)
(Figure 3B). And serum FFAs and AST obtained significant
difference in AMI compared to T2DM or control (P < .001)
(Figure 3E and F).
The participants were divided the participants into
four groups based on the age as shown in Table 3. Step-
wise multivariable regression models were used to find
the association of FFA with each of the other factors
with adjusted sex and BMI. Those factors ALT, AST, TC,
TG, HDL, LDL, BUN, TP and fasting glucose were in-
corporated into the regression models.
For stepwise multivariable regression analysis, we se-
lected the variables that were allowed to enter the model
in advance. HDL and TG were associated with The FFAs
in the control group (20 ~ 50 years) (R = 0.28, P < .001)
and were allowed to enter the multivariable model, so was
HDL was associated with FFAs in the control group
(≥60 years) (R = 0.26, P < .01) and T2DM (≥60 years) (R =
0.36, P < .05), AST was associated with The FFAs in the
AMI (≥60 years) (R = 0.487, P < .01).
Discussion
The current study demonstrates that nearly two-thirds of
patients with cardiovascular disease suffer from abnormalTable 1 The FFA levels between sexes
Sex Age (y)
n 20 ~ 50 n 50 ~ 60 n 60~
Male 145 2.60 ± 0.16 56 2.65 ± 0.18 75 2.72 ± 0.18
Female 153 2.61 ± 0.16 55 2.65 ± 0.19 56 2.73 ± 0.17
Independent-Samples T Test.glucose metabolism [15,16], and type 2 diabetes is associ-
ated with a twofold to fourfold increased risk of both cor-
onary heart disease and stroke [17]. Cardiovascular disease
was also the most common underlying cause of death in
type 2 diabetes mellitus accounting for 52% [3].
In this study, the FFA levels had a trend of increasing
with age, and no significant difference between sexes. Pre-
liminary experiments show the FFA levels were instability
in room temperature, and the difference between serum
and plasma sample was also found. Also, the detection of
FFAs is limited by the significant intra-individual range of
variation, which can be strongly influenced by food intake
and stress situations [18]. All individuals were included in
the analysis of the age greater than or equal to 60. In step-
wise multivariable regression, the FFAs were positive cor-
related with HDL in the health examination individuals or
T2DM, however, no similar correlation in the AMI. And
lower FFA was strongly associated with AST in the AMI.
FFAs serve as physiologically important energy sub-
strates and their release from the adipose tissue by lipoly-
sis is regulated according to the energy demands of the
body. FFA elevations are both a risk factor of cardiovascu-
lar disease and are associated with metabolic, atheroscler-
osis, inflammation, insulin resistance and hyperlipidemia
[19-23]. The 70% of energy was generated through
β-oxidation of fatty acids and 30% through oxidation of
ketone bodies and pyruvate in the cardiomyocytes [24,25].
A raised concentration of FFAs with subsequent increased
β-oxidation in the cardiomyocytes can be harmful for the
heart in various ways. Furthermore, increased FFAs can
lead to damage to the plasma membrane and disturbances
of the ion channels of the cardiomyocytes [25]. The fatty
acid levels has been described an increase in myocardial
infarction [26], however, we found the free fatty acid levels
has a slight decrease in the early period of acute myocar-
dial infarction, it may play an important role in the early
stage of a first-time AMI.
The ratio of low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol (LDL-c/HDL-c) is a
reliable predictor of cardiovascular risk. Low HDL-C levels
Table 2 Baseline characteristics
Control group T2DM AMI
Age (y) 71.0 ± 6.6 70.9 ± 7.3 71.3 ± 7.0
Males, n (%) 81 (56.6%) 24 (46.2%) 24 (51.1%)
BMI (kg/m2) 22.5 ± 2.6 23.5 ± 2.3** 22.3 ± 3.0
Hypertension, n (%) 15 (10.6%) 9 (17.0%) 22 (46.8%)
ALT (U/L), M (P25,P75) 20 (17,25) 23 (19,29)** 23 (19,31)##
AST (U/L), M (P25,P75) 25 (22,28) 23 (18,29) ** 25 (21,30)
Total Cholesterol (mmol/L) 4.31 ± 0.59 4.59 ± 1.03* 4.40 ± 0.90
Triglycerides (mmol/L) 1.12 ± 0.33 2.02 ± 1.29*** 1.63 ± 0.88###
HDL-cholesterol (mmol/L) 1.30 ± 0.22 0.96 ± 0.18*** 1.00 ± 0.22###
LDL-cholesterol (mmol/L) 2.35 ± 0.46 2.37 ± 0.77 2.25 ± 0.75
Glucose (mmol/l) 4.90 ± 0.49 7.75 ± 2.95*** 5.78 ± 1.32###
BUN (mmol/L) 5.50 ± 1.28 5.78 ± 3.13 6.22 ± 2.82#
Uric acid (mmol/L) 281.3 ± 68.2 316.2 ± 96.9* 366.3 ± 171.7###
HCT 41.6 ± 3.6 38.5 ± 5.2*** 38.8 ± 4.9###
WBC (10*9/L) 6.15 ± 1.60 7.30 ± 3.78** 7.12 ± 2.41#
Platelet (10*9/L) 178.7 ± 49.0 180.8 ± 63.0 182.0 ± 74.0
Total Protein (g/L) 71.1 ± 6.0 67.4 ± 6.0* 66.5 ± 6.6##
FFAs (mmol/L) 551.6 (403.0,679.7) 536.5 (412.6,666.3)*** 441.0 (298.5,625.0)
Data are presented as mean ± SD, in a normal distribution of data, or as median (inter quartile range), in a skewed distribution of data.
*P < .05, **P < .01, ***P < .001for the T2DM group vs. the control group.
#P <0.5, ##P < .01, ###P < .001 for the AMI group vs. the control group.
Figure 3 The description of six mainly levels in T2DM, AMI and control group. The histogram showed six mainly levels [TG (A), HDL (B),
LDL (C), GLU (D), AST (E), FFAs (F)] Data are mean ± SD. *P < .05, **P < .01, ***P < .001; Three groups: Control (n = 143), T2DM (n = 52), AMI (n = 47).
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Table 3 Stepwise multivariable regression model of the
serum FFA levels
Males, n (%) Age (y) Log (FFA) FFA
R P-value
Control
(20 ~ 50 years)
145 (48.7%) 39.3 ± 8.6 2.61 ± 0.16
HDL + TG 0.28 P < .001
Control
(≥60 years)
81 (56.6%) 71.0 ± 6.6 2.72 ± 0.16
HDL 0.26 P = 0.002
T2DM
(≥60 years)
24 (46.2%) 70.9 ± 7.3 2.72 ± 0.13
HDL 0.36 P = 0.01
AMI
(≥60 years)
24 (51.1%) 71.3 ± 7.0 2.64 ± 0.22
AST 0.49 P = 0.005
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a high risk for cardiovascular events [27]. LDL-c and non-
HDL-c are likely to be the predictors of cardiovascular risk
and as targets for treatment [28,29].
The liver transaminases, especially aspartate trans-
aminase (AST), were first found their use in myocardial
injury and necrosis in 1954 [30]. A total of 1783 patients
study: AST was elevated above the upper limit of normal
in 85.6% in acute myocardial infarction, CK-MB was as-
sociation with AST (r = 0.727), and independently asso-
ciated with worse mortality and clinical outcomes [31].
FFAs may serve as physiologically important energy in
AMI patients, and play as protective factors during the
acute attack period of the AMI.Conclusions
In conclusion, we found lower serum FFA levels in AMI
during the acute attack period compared to the other
two groups, independent of age, sex, BMI, the serum
HDL levels were lower in both AMI and T2DM com-
pared to control group, and AST levels were higher in
AMI compared to control group. With stepwise multi-
variable regression analysis: the HDL was associated
with the FFAs in control group and T2DM patients, but
the AST was associated with the FFAs in the AMI, the
FFAs possibly play importance roles in the AMI.
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